NASDAQ$MGNX
MacroGenics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results and corporate progress for the year ended December 31, 2022.
MacroGenics reported its 2022 financial results, highlighting a cash runway extended through 2025, modifications to the TAMARACK study design, and encouraging lorigerlimab monotherapy clinical data. The company added $250 million in non-dilutive funding over the past eight months and anticipates submitting an IND application for a new ADC later this year.
- Cash runway extended through 2025 with $250 million in non-dilutive funding over past eight months.
- TAMARACK study design modified with objective of accelerating data readout.
- Encouraging lorigerlimab monotherapy clinical data presented at ASCO-GU.
- FDA approved TZIELD to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D.
Headline financials
Revenue & EPS history
MacroGenics · Revenue · Quarterly
$73.1M
Revenue by segment
MacroGenics · $9.5M total across 3 segments · Q3 2023
- Product Sales$4.7M—49.4%
- Contract Manufacturing$4.46M+290.7%47.0%
- Government Agreements$345K-36.9%3.6%
Forward guidance
MacroGenics anticipates that its cash, cash equivalents and marketable securities balance of $154.3 million as of December 31, 2022, plus the $100 million proceeds received from DRI related to the sale of the Company’s TZIELD royalty interest, projected and anticipated future payments from partners and product revenues should extend its cash runway through 2025.
Tailwinds
- Cash, cash equivalents and marketable securities balance of $154.3 million as of December 31, 2022
- $100 million proceeds received from DRI related to the sale of the Company’s TZIELD royalty interest
- Projected and anticipated future payments from partners
- Product revenues should extend its cash runway through 2025
- Expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial
Headwinds
- The Company’s expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial
- The planned Phase 2 study of lorigerlimab in mCRPC as well as MacroGenics’ other clinical and preclinical studies currently ongoing.
- Risks that TZIELD, vobramitamab duocarmazine, lorigerlimab, MARGENZA or any other product candidate’s revenue, expenses and costs may not be as expected
- Risks relating to TZIELD, vobramitamab duocarmazine, lorigerlimab, MARGENZA or any other product candidate’s market acceptance, competition, reimbursement and regulatory actions
- Business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises such as the novel coronavirus (referred to as COVID-19 pandemic)
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+5.6%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+3.4%
Avg return
30 days after
44%
23 / 52 earnings
Positive
+251.7%
Q1 2020
Best reaction
-77.4%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | +24.0% | +12.9% | |
| Q4 2025 | +45.3% | +27.1% | +45.8% | |
| Q3 2025 | +8.3% | +4.8% | -4.8% | |
| Q1 2025 | +0.0% | +0.0% | -5.1% | |
| Q4 2024 | -4.8% | -25.7% | -40.0% | |
| Q3 2024 | +13.2% | +17.6% | -8.4% | |
| Q2 2024 | -5.6% | -1.7% | -5.6% | |
| Q1 2024 | -77.4% | -69.6% | -69.1% | |
| Q4 2023 | -18.8% | -18.0% | -15.0% | |
| Q3 2023 | +20.0% | +20.5% | +62.7% | |
| Q2 2023 | +26.6% | +13.7% | +4.7% | |
| Q1 2023 | -0.4% | -9.1% | -28.2% | |
| Q4 2022 | +8.4% | +3.7% | +0.6% | |
| Q3 2022 | +22.1% | +30.1% | +42.3% | |
| Q2 2022 | +16.2% | +18.9% | -3.6% | |
| Q1 2022 | -15.2% | -38.2% | -56.5% | |
| Q4 2021 | -3.6% | -8.1% | -12.7% | |
| Q3 2021 | +4.1% | +5.1% | -16.7% | |
| Q2 2021 | -5.5% | -5.7% | -10.3% | |
| Q1 2021 | -8.3% | -9.8% | -8.8% | |
| Q4 2020 | +18.7% | +16.1% | +57.6% | |
| Q3 2020 | +4.9% | +0.9% | +19.9% | |
| Q2 2020 | -1.5% | +3.1% | +5.9% | |
| Q1 2020 | +251.7% | +184.5% | +186.4% | |
| Q4 2019 | +8.5% | -20.8% | -45.5% | |
| Q3 2019 | -0.9% | -6.5% | +13.9% | |
| Q2 2019 | -0.3% | -9.1% | -2.5% | |
| Q1 2019 | +3.4% | +9.7% | +9.4% | |
| Q4 2018 | -2.8% | -5.8% | -19.4% | |
| Q3 2018 | +8.7% | -1.0% | -2.3% | |
| Q2 2018 | +6.3% | +9.5% | +11.1% | |
| Q1 2018 | -9.2% | -7.8% | +2.8% | |
| Q4 2017 | +2.1% | +17.7% | +2.4% | |
| Q3 2017 | -1.6% | -0.3% | +8.9% | |
| Q2 2017 | +6.6% | +8.0% | +17.8% | |
| Q1 2017 | -1.7% | -12.2% | -9.9% | |
| Q4 2016 | -5.1% | -2.7% | -15.8% | |
| Q3 2016 | -16.3% | -6.0% | +10.4% | |
| Q2 2016 | +6.8% | +1.1% | -2.2% | |
| Q1 2016 | -5.8% | — | — | |
| Q4 2015 | +5.1% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | -12.1% | — | — | |
| Q1 2015 | +9.5% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | +17.5% | — | — | |
| Q2 2014 | -4.8% | — | — | |
| Q2 2013 | -4.8% | — | — | |
| Q1 2014 | -5.0% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2013 | -7.6% | — | — | |
| Q3 2013 | +7.3% | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro